Editor’s Note: This article was published in Pharmaceutical Technology Europe’s January 2024 print issue.
OR WAIT null SECS
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Clarivate has released its 2024 Drugs to Watch report, highlighting 13 therapies with great potential.
Across the Western world, the number 13 is commonly considered to be unlucky; so much so that in many aspects of life, such as hotel floors, aeroplane seat rows, and even house numbers, the use of 13 is avoided completely. Popular theories about the basis for this superstitious belief include the arrival of Judas Iscariot at the Last Supper and the Norse god Loki at a dinner party in Valhalla, as both were the 13th guest, and both are associated with negative outcomes (1).
However, in 2024, for the bio/pharma industry, 13 may prove to be lucky, certainly for the companies whose drugs have been revealed as ‘ones to watch’ in Clarivate’s latest annual report (2). Each year, analysts from Clarivate evaluate drugs in development and discern, using certain factors, which ones they believe will be blockbusters (reaching $1 billion in annual sales) or will be therapeutic game changers.
Editor’s Note: This article was published in Pharmaceutical Technology Europe’s January 2024 print issue.
“The fundamentals underpinning the biopharma sector have never been stronger, with new technologies fuelling medical advancements and providing treatment options to patients with previously unmet needs,” said Mike Ward, global head of Thought Leadership, Life Sciences and Healthcare, Clarivate, in a press release (3). “Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year’s Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes.”
From their analysis for 2024, the Clarivate experts created a list of 13 late-stage therapies that cover a wide number of conditions, including breast cancer, multiple myeloma, sickle cell disease, and respiratory syncytial virus (RSV). The ‘Drugs to Watch’ for 2024 are:
If prior year’s predictions and analyses by Clarivate experts are anything to go by, then 13 might very well be considered lucky in bio/pharma for 2024.
Felicity Thomas is the European/senior editor for Pharmaceutical Technology Group.
Pharmaceutical Technology Europe
Vol. 36, No. 1
January 2024
Page: 6
When referring to this article, please cite it as Thomas, F. Unlucky for Some. Pharmaceutical Technology Europe 2024 36 (1) 6.
Related Content: